Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. - Wikidata - wikimedia - TriplyDB

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

http://www.wikidata.org/entity/Q33386324

about

Follicular lymphoma: 2012 update on diagnosis and management Adverse effects of biologics: a network meta-analysis and Cochrane overview Follicular lymphoma: 2011 update on diagnosis and management Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Rituximab resistance.Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.The role of angiogenesis in human non-Hodgkin lymphomas.Bortezomib for the treatment of non-Hodgkin's lymphoma The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results.Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma.Novel treatment regimens for Waldenström's macroglobulinemia.Follicular lymphoma: emerging therapeutic strategies.Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.Novel agents in indolent lymphomas.Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.Immunotherapy for B-cell lymphoma: current status and prospective advances Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.

P2860

Q22252956-7CDC5C36-A079-4C00-954C-E2AE4A69E06A Q24234197-79ADA67D-BD79-42B2-90DF-03C5340C345B Q26851450-188AF041-01F5-4265-9E48-30BC2751C3B2 Q33385670-8E4CD1E3-36D5-4FAE-8041-9A2557A4877F Q33391725-130B8836-A924-46F7-A37F-E87416FA2311 Q33402885-4E5B220A-FAF4-4441-80C3-0BC82A9CE293 Q33403958-AE75A67D-512B-4844-B655-8218E8BC9A39 Q33404090-1C1B7FD4-C000-42EA-9932-365B2C5B8AED Q33416533-A9A11E63-C8CE-4C47-8A04-A462F75D183D Q33419840-062D1F0E-2A56-4BC2-857A-B667C74C8935 Q33696008-9AF103DE-FDE3-4976-8F40-E9197D895B03 Q33713106-32B257F9-622D-4FFE-8F78-45C119F2E04B Q34353682-83F1ECB7-89E2-4112-8CED-F18A0864100E Q34372977-65573D30-A9EB-4D13-9007-AA6F2FF4B1F2 Q34521260-243B7694-62A3-4FF1-BD0F-0BBD91CC9AFC Q34707136-3A2EC6F1-3203-4DD6-9157-2454662CEDE7 Q35041270-20667B39-ED37-41BB-868A-3030EE386954 Q35050501-3AE49C55-183A-4EFE-89A1-DEF1D8C00794 Q35206717-F4C51527-FB9F-4C91-B05F-B630668522AD Q35779961-20839D95-9BF3-4F15-B812-7A6983674677 Q35905929-E2FC4C8C-E279-4300-92AA-913E0A331950 Q35989980-39721E9C-31D1-4280-AC40-132F30E28BDF Q36057877-0D163121-BD81-4EF0-B919-10A71F334578 Q36670881-F615D5CC-87E4-4103-9A5A-EB895F635F8B Q36868056-034AC5BA-01D8-4EF6-9FB1-AC59B9BE236F Q37140809-7390D53D-2372-4075-A6D7-AEC8807C3F9F Q37178611-D641EA83-768F-46B7-AE10-0CEE66119D58 Q37195045-51D228A8-FEC3-4AD5-8FD0-C42D8CCF321A Q37587057-1864900A-8B6A-4FAD-8349-C4550875AE50 Q37786616-3142441A-083C-4F77-8AA0-4BAD439AEB5D Q37810101-CC2A3775-78F7-41D3-BD8E-148A4D226778 Q37810129-ECCB2CA0-BE33-4E70-9F0E-E0CA10759EFD Q38034939-ED1D1755-A532-4AAB-BB51-4750C9BDD0F7 Q38273851-85C52756-F968-403B-8652-7464C9AFC1FC Q39431412-2F136CB2-6CE6-49D4-9357-D200C360722D Q39627475-ABB4C56F-6435-4FF1-A82B-02B524971EE4 Q40333043-C669E2E7-BB2F-47E9-98EE-3A3A826105A5 Q41831989-4E997257-856F-4C5D-8B5E-E752F3F7BB38 Q43138254-74BF58EA-E364-4355-8054-E53326F3CB06 Q44100018-9DECAA23-BBEC-451A-B955-4418E39B0080

P2860

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

http://www.wikidata.org/entity/Q33386324

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Multicenter randomized phase I ...... marginal-zone B-cell lymphoma.

@ast

Multicenter randomized phase I ...... marginal-zone B-cell lymphoma.

@en

type

label

Multicenter randomized phase I ...... marginal-zone B-cell lymphoma.

@ast

Multicenter randomized phase I ...... marginal-zone B-cell lymphoma.

@en

prefLabel

Multicenter randomized phase I ...... marginal-zone B-cell lymphoma.

@ast

Multicenter randomized phase I ...... marginal-zone B-cell lymphoma.

@en

P1433

Q33386324-12FCA7DC-50BA-45F7-9E53-75358CF007E7

P1476

Q33386324-97554EC0-86F8-41B2-ACD0-F069F4CB1D5C

P2093

Q33386324-0525A3AD-93D5-41F5-B293-1A5A92CEBBCC

Q33386324-14D50E7A-CF9D-4C4B-93AE-0A3B9837DB58

Q33386324-186EAF04-C4BD-4355-9879-52386BDA7FFB

Q33386324-27F9DFFF-947B-4A27-823F-9ABC2CAE5D8F

Q33386324-2AD6C25E-BB41-4739-99A2-C5BF0922460C

Q33386324-3292A820-321F-4493-BC0D-339759BCAE36

Q33386324-569B5D24-23FD-4EF8-B2FC-4FB521C49D14

Q33386324-69F4123E-8AC0-41ED-B76C-C562FB67A4DA

Q33386324-8732889A-906E-4A9C-9F21-72CA527BAD0F

Q33386324-A7863D55-0F43-4D90-8231-F0AC6E6EE10D

P304

Q33386324-3FFBAE2D-0A89-4C9F-86F0-EEDD622180BD

P31

Q33386324-653929F4-D00F-46ED-935A-2588D0657FFA

P356

Q33386324-EC93576F-4DEB-435D-9A30-312FD2A81879

P407

Q33386324-D95F549E-7C57-4374-97FF-9C00F6A45DD2

P433

Q33386324-587B03DF-634B-46B2-866F-DC55219A24D1

P478

Q33386324-B6565615-6539-4C1F-83DB-49C2F83890BE

P577

Q33386324-9783A198-87E8-497A-88AB-1C31141E7519

P5875

Q33386324-39A70C53-C047-44B1-8EC1-E3D4DF7E90D0

P698

Q33386324-10A008FC-6F44-4C77-87D0-74E326C7429A

P921

Q33386324-D622AA40-A90B-470A-B4FD-B62E98AD25DB

P356

JCO.2008.17.7980

P1433

Journal of Clinical Oncology

P1476

Multicenter randomized phase I ...... marginal-zone B-cell lymphoma.

@en

P2093

André Goy

http://www.w3.org/2001/XMLSchema#string

Anthony L Boral

http://www.w3.org/2001/XMLSchema#string

Charles Holladay

http://www.w3.org/2001/XMLSchema#string

Christopher R Flowers

http://www.w3.org/2001/XMLSchema#string

Dipti Patel-Donnelly

http://www.w3.org/2001/XMLSchema#string

Lowell Hart

http://www.w3.org/2001/XMLSchema#string

Mansoor N Saleh

http://www.w3.org/2001/XMLSchema#string

Mark Knapp

http://www.w3.org/2001/XMLSchema#string

Martha Glenn

http://www.w3.org/2001/XMLSchema#string

Peter McLaughlin

http://www.w3.org/2001/XMLSchema#string

P304

5023-5030

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.17.7980

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26827755

http://www.w3.org/2001/XMLSchema#string

P698

19770386

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial